로딩 중…
지수 로딩 중…
이수앱지스
086890· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩3,250-2.11%
2026-06-19
Price Chart
이수앱지스-37.62%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 132.52B KRW |
| Revenue | 58.94B KRW |
| Net Income | -2.12B KRW |
| Total Assets | 153.02B KRW |
| Net Assets | 115.42B KRW |
| Employees | 190 |
| Value | |
| P/B | 1.15x |
| P/S | 2.25x |
| FCF Yield | 5.07% |
| Profitability | |
| ROE | -1.84% |
| ROA | -1.38% |
| Op. Margin | -2.28% |
| Revenue Growth | 31.59% |
| Earnings Growth | -172.55% |
| Financial Health | |
| Debt Ratio | 132.58% |
| Total Debt | 18.08B KRW |
| FCF | 6.71B KRW |
| Cash | 17.64B KRW |
| Current Ratio | 2.16x |
| Performance | |
| 1Y Return | -37.62% |
| 1M Return | -13.56% |
| From 52W High | -48.82% |
| 1Y MDD | -51.12% |
| Trading | |
| Volume | 144,567 shares |
| Foreign Own. | 2.51% |
| Per Share | |
| EPS | -54 KRW |
| BPS | 2,831 KRW |
Company Info
Established in 2001, Isu Abxis is a specialized company that develops, manufactures, and sells biotechnology-based therapeutic antibodies and proteins, having been special listed on the KOSDAQ market in 2009. Its key therapeutic products include Abcertin, Pabagal, Clotynap, Feburain, Trientop, and Casavan, and it continues to grow in its unique field. The company is promoting export expansion and market diversification, notably by signing sales right contracts for Pabagal in 11 countries including Russia and Taiwan. Isu Abxis is also reviewing the development of therapeutic products for cancer and intractable diseases and is headquartered in Seongnam-si, Gyeonggi-do.